30mil CAD$ Investment in European Centre of Cancer Immunotherapy

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Helix Immuno-Oncology (“HIO”) has signed a non-binding letter of intent with KEN Poland Limited Liability Partnership (“KEN POLAND”) in support of the European Centre for Cancer Immunotherapy (“ECCI”).

The letter of intent signed on January 31, 2017, confirms the common intention of HIO and KEN POLAND of establishing a cooperation and initiating a framework of investment in the ECCI, using the innovative Helix CAR-T and DOS47 technologies. The letter of intentcontemplates a proposed investment by KEN POLAND of approximately $30 million (CAD) with additional financing for the venture
to be sought from both private and public sources. The ECCI is planned to consist of five satellite clinics located in existing Polish hospitals and a planned central clinic providing access to cancer patients requiring immune-based therapies.